| Literature DB >> 19428598 |
Min Zhuang1, Hong Jiang, Yasuhiro Suzuki, Xiaoguang Li, Peng Xiao, Takashi Tanaka, Hong Ling, Baofeng Yang, Hiroki Saitoh, Lianfeng Zhang, Chuan Qin, Kazuo Sugamura, Toshio Hattori.
Abstract
We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC(50S), 283.4+/-16.3 and 149.5+/-13.5 microg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC(50S), 43.1+/-2.8 and 7.8+/-0.3 microg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC(50S), 29.9+/-3.3 and 41.3+/-3.4 microM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19428598 PMCID: PMC7114128 DOI: 10.1016/j.antiviral.2009.02.001
Source DB: PubMed Journal: Antiviral Res ISSN: 0166-3542 Impact factor: 5.970
Fig. 1Fractionation procedure of Cinnamomi Cortex (see text).
Inhibitory effects of medicinal herbs on infection of HIV/SARS-CoV S pseudovirus.
| Extracts | CC50 (μg/ml) | IC50 (μg/ml) | SI (CC50/IC50) |
|---|---|---|---|
| Forsythiae Fructus | 577.8 ± 79.7 | 401.4 ± 29.5 | 1.4 |
| Scutellariae Radix | 854.2 ± 76.2 | 853.2 ± 36.8 | 1.0 |
| Astragali Radix | 2726.5 ± 125.2 | 1623.7 ± 106.5 | 1.7 |
| Bupleuri Radix | 1213.6 ± 54.5 | 1643.2 ± 52.8 | <1 |
| Glycyrrhizae Radix | 741.2 ± 70.7 | 781.2 ± 65.4 | <1 |
| Cinnamomi Cortex (CCE) | 201.1 ± 17.1 | 30.3 ± 2.6 | 6.6 |
| Ethanol extract of CC (Fr.1) | 444.0 ± 13.7 | 85.3 ± 7.5 | 5.2 |
| Butanol fraction of CC (Fr.2) | 205.3 ± 11.2 | 37.3 ± 3.5 | 5.5 |
| Aqueous fraction of CC (Fr.3) | 267.7 ± 23.6 | 68.6 ± 5.7 | 3.9 |
| Ethylacetate fraction of CC (Fr.4) | 197.8 ± 14.1 | 58.1 ± 4.4 | 3.4 |
| Caryophylli Flos (CFE) | 757.2 ± 59.3 | 58.8 ± 5.6 | 12.9 |
| Ethanol extract of CF (Fr.1) | 553.4 ± 35.7 | 102.0 ± 7.3 | 5.4 |
| Butanol fraction of CF (Fr.2) | 1074.7 ± 82.0 | 51.3 ± 4.9 | 20.9 |
| Aqueous fraction of CF (Fr.3) | 1573.1 ± 88.2 | 67.1 ± 5.3 | 23.4 |
| Ethylacetate fraction of CF (Fr.4) | 441.5 ± 14.5 | 60.4 ± 5.5 | 7.3 |
Experiments were repeated three times, and the averages of IC50 (the inhibitory concentration of extract to inhibit the luciferase activity to 50% control value) and CC50 (the cytotoxic concentration of extract that reduced cell viability to 50%) are shown. The selectivity index (SI) corresponds to CC50/IC50.
Fig. 2Inhibition of pseudovirus infection by medicinal herbs. Pseudoviruses were treated with the following extracts and then incubated on the target cells. HIV/SARS-CoV S pseudovirus (A) or HIV/VSVG pseudovirus (B) was mixed with or without the reagents and was then added to HepG2 cells for infection. Target cells were treated by the extracts for 1 h followed by infection of HIV/SARS-CoV S pseudovirus (C) or HIV/VSVG pseudovirus (D) infection. The extracts used were as follows: (□) CCE; () CC/Fr.1; (■) CC/Fr.2; () CC/Fr.3; () CC/Fr.4; () CFE. The experiment was repeated three times and the average is shown. The error bar indicates standard deviation (SD).
Inhibitory effects of medicinal herbs and their fractionated samples on infection by wild-type SARS-CoV.
| Extracts | CC50 (μg/ml) | IC50 (μg/ml) | SI |
|---|---|---|---|
| Cinnamomi Cortex extract (CCE) | 360.2 ± 23.0 | 43.1 ± 2.8 | 8.4 |
| Ethanol extract of CC (Fr.1) | 180.5 ± 5.8 | 10.7 ± 0.4 | 16.9 |
| Butanol fraction of CC (Fr.2) | 180.0 ± 6.0 | 7.8 ± 0.3 | 23.1 |
| Aqueous fraction of CC (Fr.3) | 360.0 ± 19.7 | 39.7 ± 2.1 | 9.1 |
| Ethylacetate fraction of CC (Fr.4) | 90.1 ± 4.6 | – | – |
| Caryophylli Flos extract (CFE) | 180.0 ± 5.2 | 50.1 ± 3.5 | 3.6 |
| Ethanol extract of CF (Fr.1) | 50.5 ± 4.7 | – | |
| Butanol fraction of CF (Fr.2) | 15.0 ± 0.8 | – | |
| Aqueous fraction of CF (Fr.3) | 310.0 ± 16.3 | – | |
| Ethylacetate fraction of CF (Fr.4) | 35.1 ± 2.8 | – | |
Experiments were repeated three times, and the data show the average IC50 (the inhibitory concentration of extracts for a 50% plaque reduction of the virus). SI corresponds to CC50/IC50. ‘–’ indicates that the extracts did not inhibit SARS-CoV infection at the highest optimal concentration.
Inhibitory effects of chemical reagents on infection of HIV/SARS-CoV S pseudovirus.
| No. | Extracts | CC50 (mM) | IC50 (mM) | SI (CC50/IC50) |
|---|---|---|---|---|
| 1 | 0.2 ± 0.014 | 0.2 ± 0.016 | 1 | |
| 2 | 22.4 ± 1.230 | 3.0 ± 0.178 | 7.4 | |
| 3 | Licochalcone-A | 0.03 ± 0.001 | 0.03 ± 0.003 | 1 |
| 4 | 2-Phenylethanol (phenethy alcohol) | 24.5 ± 1.533 | 4.1 ± 0.199 | 6.0 |
| 5 | 2′-Hydroxyacetophenone ( | 1.8 ± 0.071 | 1.8 ± 0.102 | 1 |
| 6 | Isoeugenol | 3.9 ± 0.343 | 2.0 ± 0.142 | 2.0 |
| 7 | 2-Hydroxycinnamic acid | 2.5 ± 0.122 | 0.3 ± 0.013 | 8.3 |
| 8 | 3,4-Dimethoxycinnamic acid | 10.0 ± 0.620 | 5.0 ± 0.233 | 2 |
| 9 | 4-Hydroxy-3-methoxycinnamic acid (ferulic acid) | 10.0 ± 0.555 | 5.0 ± 0.312 | 2 |
| 10 | 4-Hydroxy-3-methoxy cinnamaldehyde | 0.7 ± 0.043 | 0.3 ± 0.013 | 2.3 |
| 11 | 4-Hydroxycoumarin | 10.3 ± 0.660 | 10.3 ± 0.500 | 1 |
| 12 | 7-Hydroxycoumarin | 10.7 ± 0.560 | 2.5 ± 0.172 | 4.3 |
| 13 | 75.0 ± 4.350 | 75.0 ± 5.550 | 1 | |
| 14 | 4-Allylanisole | 8.0 ± 0.563 | 8.4 ± 0.650 | <1 |
| 15 | Ethylcinnamate | 14.1 ± 1.220 | 7.1 ± 0.532 | 2.0 |
| 16 | Cinnamylacetate | 7.1 ± 0.420 | 7.1 ± 0.350 | 1 |
Experiments were repeated three times, and the averages of IC50 (the inhibitory concentration of extract to inhibit the luciferase activity to 50% control value) and CC50 (the cytotoxic concentration of extract that reduced cell viability to 50%) are shown. SI corresponds to CC50/IC50.
The effects of compounds fractionated from CC on HIV/SARS-CoV S and SARS-CoV wild-type.
| Compounds | MW | HIV/SARS-CoV S pseudovirus infection | Plaque reduction assay on SARS-CoV | ||||
|---|---|---|---|---|---|---|---|
| CC50 (μM) | IC50 (μM) | SI | CC50 (μM) | IC50 (μM) | SI | ||
| Procyanidin A2 | 576.512 | 796.6 ± 63.7 | 120.7 ± 13.1 | 6.60 | 1116.7 ± 60.3 | 29.9 ± 3.3 | 37.35 |
| Procyanidin B1 | 578.528 | 656.2 ± 36.7 | 161.1 ± 20.3 | 4.08 | 648.2 ± 43.4 | 41.3 ± 3.4 | 15.69 |
| Cinnamtannin B1 | 864.769 | 242.3 ± 14.8 | 32.9 ± 2.8 | 7.36 | 184.7 ± 15.5 | 32.9 ± 3.9 | 5.61 |
Experiments were repeated three times, and the averages of IC50 and CC50 are shown. SI corresponds to CC50/IC50.
Fig. 3Effect of medicinal herbs on TfR or CD59 expression on Jurkat cells. A dose-dependent effect was observed (A and B). Jurkat cells were treated with various concentrations of the following extracts for 1 h followed by two-color staining with PE-anti-TfR (A) and FITC-anti-CD59 (B). A time-dependent effect was also observed (C and D). Jurkat cells were treated with the various extracts for 0–60 min and were analyzed with PE-anti-TfR (C) and FITC-anti-CD59 (D). (□) CCE; (▵) CC/Fr.1; (♢) CC/Fr.2; (●) CC/Fr.3; (■) CC/Fr.4; (○) DMSO. Y-axis indicates MFI (mean fluorescence intensity) % of control. The experiment was repeated three times and the average is shown. The error bar indicates standard deviation (SD).
Fig. 4The effects of procyanidin A2 and cinnamtannin B1 on TfR or CD59 expression on Jurkat cells. The dose- and time-dependent effects of procyanidin A2 and cinnamtannin B1 on Jurkat cells were examined. Jurkat cells were treated with various concentrations of procyanidin A2 and cinnamtannin B1 for 1 h (A) or were treated with 300 μM of procyanidin A2 and 100 μM of cinnamtannin B1 for various periods (B), following PE-anti-TfR and FITC-anti-CD59 staining flow cytometry was applied. (■) FITC-anti-CD59-procyanidin A2; (●) FITC-anti-CD59-cinnamtannin B1; (□) PE-anti-TfR-procyanidin A2; (○) PE-anti-TfR-cinnamtannin B1. The experiment was repeated three times and the average is shown. The error bar indicates standard deviation (SD).
Fig. 5CCE and CC/Fr.2 affect the internalization of Tfn-A488 at the plasma membrane. Jurkat cells were treated with different concentration of CCE or CC/Fr.2 at 4 °C for 30 min. Then A488-conjugated transferrin was added and incubated at 4 °C for 30 min. After washing the Jurkat cells were incubated at 37 °C for 0 or 15 min in the presence or absence of the extracts. The nucleus is stained with DAPI. The results are representative of at least three independent experiments and numbers are provided in Section 3. Bar, 5 μm for all panels.
The internalization of Tfn-A488 in Jurkat cells after treatment with the extracts.
| Extracts | Internalization of Tfn-A488 | ||
|---|---|---|---|
| 100 μg/ml | 10 μg/ml | 6 μg/ml | |
| CCE | − | + | + |
| Ethanol extract of CC (Fr.1) | − | + | + |
| Butanol fraction of CC (Fr.2) | − | − | + |
| Aqueous fraction of CC (Fr.3) | − | + | + |
| Ethylacetate fraction of CC (Fr.4) | + | + | + |
| CFE | + | + | + |
| Ethanol extract of CF (Fr.1) | + | + | + |
| Butanol fraction of CF (Fr.2) | + | + | + |
| Aqueous fraction of CF (Fr.3) | + | + | + |
| Ethylacetate fraction of CF (Fr.4) | + | + | + |
‘−’ indicates that no internalization of Tfn-A488 was observed in 30 fields of observation. ‘+’ indicates that the internalization of Tfn-A488 was observed in 30 fields of observation. The results are representative of at least three independent experiments.
Fig. 6Procyanidin A2, procyanidin B1 and cinnamtannin B1 are structurally very similar.